Journals / Klinik Psikofarmakoloji Bülteni / 2009 / Cilt: 19 - Sayı: 2

Depresif bozukluğu olan hastalarda selektif serotonin geri alım inhibitörlerinin işitsel beyin sapı yanıtları üzerine etkileri

Effects of selective serotonin reuptake inhibitors on auditory brainstem responses in patients with depressive disorder

Pages
113–118
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

I-V and III-V interpeak latencies of the right ears and I-III interpeak latencies of the left ears of the patients after the 2nd week of treatment were determined significantly longer than the control group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: It is well known that the action of selective serotonin reuptake inhibitors (SSRIs) on the serotonergic system is not regionally specific.
📊
Key Findings & Data:We aimed to evaluate the effects of SSRIs on auditory brainstem responses in patients with depressive disorder.Material and Methods: Measurement of auditory brainstem response (ABR), Beck Depression Inventory (BDI) and Clinical Global Impressions-Severity of Illness Scale(CGI) were performed to the patients who have depressive disorder diagnosis based on DSM-IV criteria, before SSRI treatment (n=51) and after completing the 2nd week (n=51) and 2nd month (n=32) of the treatment.
💡
Conclusion & Impact:I-V and III-V interpeak latencies of the right ears and I-III interpeak latencies of the left ears of the patients after the 2nd week of treatment were determined significantly longer than the control group (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: It is well known that the action of selective serotonin reuptake inhibitors (SSRIs) on the serotonergic system is not regionally specific. We aimed to evaluate the effects of SSRIs on auditory brainstem responses in patients with depressive disorder.Material and Methods: Measurement of auditory brainstem response (ABR), Beck Depression Inventory (BDI) and Clinical Global Impressions-Severity of Illness Scale(CGI) were performed to the patients who have depressive disorder diagnosis based on DSM-IV criteria, before SSRI treatment (n=51) and after completing the 2nd week (n=51) and 2nd month (n=32) of the treatment. The result were compared to the results of control group, which included 34 healthy volunteers similar to the study group in terms of age and sociodemographic characteristics.Results: The BDI scores of the patients were 33.5±5.1, 30.6±4.6 and 13.0±3.5 before the treatment, after the 2nd week and 2nd month of the treatment, respectively. CGI scores of the patients were 5.0±0.7, 4.2±0.8, 1.2±0.7 before the treatment, after the 2nd week and 2nd month of the treatment respectively. There was no significant difference in terms of absolute latency and interpeak latencies of ABR on both right and left ears between the control and patient groups before the treatment and after 2nd month of the treatment (p>0.05 for all statistical). I-V and III-V interpeak latencies of the right ears and I-III interpeak latencies of the left ears of the patients after the 2nd week of treatment were determined significantly longer than the control group (p

Özet

Amaç: Selektif serotonin reuptake inhibitörlerinin (SSRI) serotonerjik sistemdeki etkisinin spesifik bir bölgede olmadığı iyi bilinmektedir. Bu çalışmada, depresif bozukluğu bulunan hastalarda SSRI’ların işitsel beyin sapı yanıtları üzerine olan etkisini değerlendirmeyi amaçladık.Yöntem: DSM-IV kriterlerine göre depresif bozukluk tanısı olan hastalara işitsel beyin sapı yanıtları (ABR), Beck Depresyon Envanteri ve Klinik Global İzlenim-Şiddet ölçeği tedavi öncesi (n=51), tedaviden 2 hafta sonra (n=51) ve tedaviden 2 ay sonra (n=32) yapıldı. Sonuçlar, yaş ve demografik özellikler açısından çalışma grubuna benzeyen 34 sağlıklı gönüllüden oluşan kontrol grubuyla karşılaştırıldı.Bulgular: Hastaların, Beck Depresyon ölçeği skorları tedavi öncesi 33.5±5.1, tedaviden 2 hafta sonra 30.6±4.6 ve tedaviden 2 ay sonra 13.0±3.5 olarak saptandı. Klinik Global İzlenim-Şiddet ölçeği skorları tedaviden önce 5.0±0.7, tedaviden 2 hafta sonra 4.2±0.8 ve tedaviden 2 ay sonra ise 1.2±0.7 olarak bulundu. Tedavi öncesi ve tedaviden 2 ay sonraki kontrol grubu ABR dalga mutlak latans ve interpik latans değerleri ile hasta grubu değerleri arasında her iki kulak için anlamlı fark saptanmadı (p>0.05). Hastaların tedaviden 2 hafta sonraki sağ kulak I-V ve III-V interpik latans değerleri ile sol kulak I-III interpik latans değerleri kontrol grubuna göre anlamlı olarak daha uzamış saptandı (p

🔖

Cite This Article

DEREKÖY, S., AYÇİÇEK, A., ÖZBULUT, Ö., DUMAN, K., KENAR, F., GEÇİCİ, Ö. (2022). Depresif bozukluğu olan hastalarda selektif serotonin geri alım inhibitörlerinin işitsel beyin sapı yanıtları üzerine etkileri. Klinik Psikofarmakoloji Bülteni, Cilt: 19 - Sayı: 2, 113–118. https://ajindex.com/articles/574250

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Tadros SF, D'Souza M, Zettel ML, Zhu X, Lynch-Erhardt M, Frisina RD. Serotonin 2B receptor: upregulated with age and hearing loss in mouse auditory system. Neurobiol Aging 2007; 28:1112-1123
  2. Wilkinson LO, Dourish CT. Serotonin and animal behavior. In: Serotonin receptor subtypes: basic and clinical aspects, Peroutka SJ (editors), New York: Wiley-Liss, 1991:147-210
  3. Cruz OLM, Kase CA, Sanchez M, Barbosa F, Barros FA. Serotonin reuptake inhibitors in auditory processing disorders in elderly patients: preliminary results. The Laryngoscope 2004; 114:1656-1659
  4. Heninger GR, Delgado PL, Charney DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996; 29:2-11
  5. Debener S, Strobel A, Kürschner K, Kranczioch C, Hebenstreit J, Maercker A, Beauducel A, Brocke B. Is auditory evoked potential augmenting/reducing affected by acute tryptophan depletion? Biol Psychol 2002; 59:121-133
  6. Schatzberg AF, Nemeroff CB. Klinik Psikofarmakolojinin Esasları. Çeviri editörleri: Ceylan ME, Ger C, Arısoy Ö. 1. baskı,. Esin Ofset Matbaa ve Reklamcılık A.Ş, 2005; 29-45
  7. Carrasco JL, Sandner C. Clinical effects of pharmacologic variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract 2005;59:1428-1434
  8. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57:507-513
  9. Kuloğlu M, Atmaca M, Geçici Ö, Nülüfer Kılıç N,Tezcan AT. The side- effects of antidepressants on sexual functıon. Bull Clin Psychopharmacol 2000; 10:97-102 (In Turkish)
  10. Atmaca M, Kuloğlu M, Geçici Ö, Tezcan AE. Sildenafil use in antidepressant drugs induced erectile dysfunction. Bull Clin Psychopharmacol 2001;11:106-110 (In Turkish)
  11. Gündoğar D, Dereköy S, Yılmaz D. Hearıng impairment and tinnitus during fluvoxamine treatment: case report. 39th The National Congress of Psychiatry, 14-19 October 2003, Antalya, Turkey. (In Turkish)
  12. Cunningham M, Cunningham K, Lydiard RB. Eye tics and subjective hearing impairment during fluoxetine therapy (Letter to the Editor). American Journal of Psychiatry 1990; 147: 947-948
  13. Stahl SM. Essential Psychopharmacology The Prescriber’s Guide. First publilished, Canada: Cambridge University Press, 2005: 195-200
  14. Gopal KV, Bishop CE, Carney L. Auditory measures in clinically depressed individuals. II. Auditory evoked potentials and behav